

Biotechnology and Medical Care

30.4▲0.1High 30.75 | Low 30.0

【+/-/X represent Up/Down/Not compared】


Company Information	
Company Name	ENERGENESIS BIOMEDICAL CO., LTD.
Spokesman	Chiang Ming-tsan
Website	http://www.energenesis-biomedical.com
Capital	NT 888,080,000
Main Business	Energenesis Biomedical employs unique ENERGI medicine development platform, activating AMP activated protein kinase (AMPK) and thereby enhancing cellular energy, for the cure of diseases.Energenesis Biomedical Co., Ltd. aspires to become a new star in Taiwan's biomedicine industry.
Listing Date	2023/06/12
Industry	Biotechnology and Medical Care
Investor Conference	WebPro link



Date	Closing Price	Trade Volume	Date	Closing Price	Trade Volume	Date	Closing Price	Trade Volume
8/3	30.4	56,110	7/20	34.5	191,591	7/3	37.15	251,023
7/31	30.3	132,837	7/17	33.95	252,890	7/2	35.4	69,439
7/30	29.4	310,507	7/16	35.95	192,075	7/1	35.7	54,579
7/29	30.25	463,844	7/15	35.0	82,776	6/30	36.4	81,878
7/28	31.8	227,002	7/14	33.6	119,149	6/29	36.1	77,022
7/27	33.05	138,415	7/13	34.75	84,663	6/26	34.9	130,572
7/24	34.0	185,897	7/9	35.3	94,588	6/25	35.95	100,200
7/23	35.85	76,554	7/8	36.1	131,655	6/24	35.35	138,329
7/22	35.85	125,487	7/7	37.45	202,920	6/23	35.25	123,999
7/21	36.1	171,276	7/6	36.75	95,859	6/22	36.25	224,493

Historical Trading Information

Securities Investment Trust Companies



Foreign Investors




Dealers




Date	Securities Investment Trust Companies Difference(+)/(-)	Dealers Difference(+)/(-)	Foreign Investors Difference(+)/(-)	Date	Securities Investment Trust Companies Difference(+)/(-)	Dealers Difference(+)/(-)	Foreign Investors Difference(+)/(-)
8/3	0	-2,000	+5,000	7/13	0	0	-18,000
7/31	0	+1,000	-18,000	7/9	0	0	+1,000
7/30	0	-1,000	+24,000	7/8	0	0	-17,999
7/29	0	+1,000	+210,600	7/7	0	0	+43,000
7/28	0	0	+100,000	7/6	0	0	-13,000
7/27	0	+1,000	+18,000	7/3	0	0	+91,000
7/24	0	-1,000	-50,000	7/2	0	0	-11,000
7/23	0	0	-4,000	7/1	0	0	+23,000
7/22	0	-1,000	+22,000	6/30	0	0	+37,782
7/21	0	0	+67,000	6/29	0	0	+28,000
7/20	0	+1,000	+79,500	6/26	0	0	-24,000
7/17	0	0	-1	6/25	0	0	+58,000
7/16	0	+1,000	+63,000	6/24	0	0	+57,000
7/15	0	-3,000	+35,000	6/23	0	0	+24,300
7/14	0	+4,000	-1,000	6/22	0	0	+45,000

Purchase on Margin




Short Sale




Date	Purchase on Margin	Short Sale	Date	Purchase on Margin	Short Sale	Date	Purchase on Margin	Short Sale
8/3	-6	0	7/20	-10	0	7/3	-13	0
7/31	-13	0	7/17	-4	0	7/2	-2	0
7/30	-6	0	7/16	0	0	7/1	-55	0
7/29	-25	0	7/15	0	0	6/30	0	0
7/28	-45	0	7/14	-12	0	6/29	0	0
7/27	0	0	7/13	0	0	6/26	-15	0
7/24	-14	0	7/9	-4	0	6/25	0	0
7/23	-1	0	7/8	-25	0	6/24	-1	0
7/22	-4	0	7/7	-27	0	6/23	0	0
7/21	-10	0	7/6	-1	0	6/22	-9	0

Company Financials

EPS




Income from continuing operations before tax




Quarter	Jan-Mar		Jan-Jun		Jan-Sep		Jan-Dec	
	EPS	Income from continuing operations before tax (Thousand)	EPS	Income from continuing operations before tax (Thousand)	EPS	Income from continuing operations before tax (Thousand)	EPS	Income from continuing operations before tax (Thousand)
2026	-0.53	-46,308	-	-	-	-	-	-
2025	-1.11	-96,973	-1.64	-144,602	-2.19	-193,610	-2.92	-258,402
2024	-0.56	-42,792	-1.20	-91,510	-2.38	-181,193	-3.03	-231,080
2023	-	-	-2.25	-152,890	-2.80	-198,053	-3.62	-260,382

Monthly Revenue



Monthly	Monthly Revenue	Monthly	Monthly Revenue	Monthly	Monthly Revenue	Monthly	Monthly Revenue
2026/06	502,000	2025/06	925,000	2024/06	337,000	2023/06	528,000
2026/05	541,000	2025/05	713,000	2024/05	777,000	2023/05	689,000
2026/04	809,000	2025/04	426,000	2024/04	516,000	2023/04	653,000
2026/03	730,000	2025/03	486,000	2024/03	751,000	2023/03	814,000
2026/02	270,000	2025/02	295,000	2024/02	241,000	2023/02	557,000
2026/01	391,000	2025/01	432,000	2024/01	416,000	2023/01	177,000
2025/12	1,121,000	2024/12	600,000	2023/12	615,000	2022/12	1,003,000
2025/11	555,000	2024/11	1,114,000	2023/11	1,005,000		
2025/10	1,139,000	2024/10	882,000	2023/10	615,000		
2025/09	772,000	2024/09	455,000	2023/09	810,000		
2025/08	317,000	2024/08	1,050,000	2023/08	332,000		
2025/07	493,000	2024/07	610,000	2023/07	363,000		

PE ratio



Date	PE ratio	Date	PE ratio	Date	PE ratio
8/3	0.00	7/20	0.00	7/3	0.00
7/31	0.00	7/17	0.00	7/2	0.00
7/30	0.00	7/16	0.00	7/1	0.00
7/29	0.00	7/15	0.00	6/30	0.00
7/28	0.00	7/14	0.00	6/29	0.00
7/27	0.00	7/13	0.00	6/26	0.00
7/24	0.00	7/9	0.00	6/25	0.00
7/23	0.00	7/8	0.00	6/24	0.00
7/22	0.00	7/7	0.00	6/23	0.00
7/21	0.00	7/6	0.00	6/22	0.00

Announcements

(Please refer to [mops](#) for the most updated information)

Subject	Date
▶ Announcement for the Board of Directors meeting date of the Second Quarter 2026 financial report	2026/07/30 16:43:00
▶ EB Receives Notification Regarding IND Applica- tion to U.S. FDA for PhaseII Clinical Trial of ENERGI- F705PD, an Oral Medication for Parkinson's Disease.	2026/07/27 17:01:36
▶ Announcement of EB's execution of a Technology and Patent Application Rights Assignment Agreement with its subsidiary Repurgenesis Co., Ltd.	2026/07/08 17:52:19
▶ EB Receives Notification from CRO on IND Submi- ssion to the U.S.FDA for ENERGI-F705PD PhaseII Clini- cal Trial,an Oral Medication for Parkinson's Disease.	2026/06/26 17:28:57
▶ The Company to attend investor conference held by IBF.	2026/06/10 15:26:02

Corporate Action

Year	Shareholders' meeting date	Period	Cash dividends	Stock dividends
2025	2026/05/22	2025	0.00000	0.00000
2024	2025/05/23	2024	0.00000	0.00000
2023	2024/05/24	2023	0.00000	0.00000
2022	2023/05/26	2022	0.00000	0.00000
2021	2022/05/27	2021	0.00000	0.00000